Keto Diet for Pcos Pdf
J Transl Med. 2020; 18: 104.
Effects of a ketogenic diet in overweight women with polycystic ovary syndrome
Antonio Paoli
1Department of Biomedical Sciences, University of Padua, Padua, Italy
2Research Center for High Performance Sport, UCAM, Catholic University of Murcia, Murcia, Spain
Laura Mancin
1Department of Biomedical Sciences, University of Padua, Padua, Italy
3Human Inspired Technology Research Center HIT, University of Padua, Padua, Italy
Maria Cristina Giacona
4Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy
Antonino Bianco
5Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy
Massimiliano Caprio
6Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele Pisana, Rome, Italy
7Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, Rome, Italy
Received 2019 Nov 13; Accepted 2020 Feb 19.
This article has been cited by other articles in PMC.
- Data Availability Statement
-
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Abstract
Background
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during reproductive age. It is characterised clinically by oligo-ovulation or anovulation, hyper-androgenism, and the presence of polycystic ovaries. It is associated with an increased prevalence of metabolic syndrome, cardiovascular disease and type 2 diabetes. The onset of PCOS has been associated to several hereditary and environmental factors, but insulin resistance plays a key pathogenetic role. We sought to investigate the effects of a ketogenic diet (KD) on women of childbearing age with a diagnosis of PCOS.
Methods
Fourteen overweight women with diagnosis of PCOS underwent to a ketogenic Mediterranean diet with phyoextracts (KEMEPHY) for 12 week. Changes in body weight, body mass index (BMI), fat body mass (FBM), lean body mass (LBM), visceral adipose tissue (VAT), insulin, glucose, HOMA-IR, total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides (TGs), total and free testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH); dehydroepiandrosterone sulfate (DHEAs), estradiol, progesterone, sex hormone binding globulin (SHBG) and Ferriman Gallwey score were evaluated.
Results
After 12 weeks, anthropometric and body composition measurements revealed a significant reduction of body weight (− 9.43 kg), BMI (− 3.35), FBM (8.29 kg) and VAT. There was a significant, slightly decrease of LBM. A significant decrease in glucose and insulin blood levels were observed, together with a significant improvement of HOMA-IR. A significant decrease of triglycerides, total cholesterol and LDL were observed along with a rise in HDL levels. The LH/FSH ratio, LH total and free testosterone, and DHEAS blood levels were also significantly reduced. Estradiol, progesterone and SHBG increased. The Ferriman Gallwey Score was slightly, although not significantly, reduced.
Keywords: Overweight, Ketogenic diet, PCOS, Hyperinsulinemia, LCKD, Ketone bodies, Low carbohydrate diet
Background
Polycystic ovarian syndrome (PCOS) is considered the most common endocrine disorder in women in the reproductive age, with an estimated prevalence ranging from 6 to 15%, depending on the diagnostic criteria used. PCOS, in fact, is an heterogeneous condition with variable phenotypic expression leading to significant controversy on the diagnostic criteria [1].
Women with PCOS often seek care for menstrual disturbances (oligomenorrhea, amenorrhea, prolonged irregular menstrual bleeding), clinical manifestations of hyperandrogenism and infertility. Hirsutism is a common clinical presentation of hyperandrogenism occurring in up to 70% of women with PCOS and is evaluated using the Ferriman–Gallwey scoring system [2].
Common signs of PCOS not included in diagnostic criteria are represented by insulin resistance, reversal of the FSH/LH ratio and obesity, which is an important clinical feature of PCOS. Women with PCOS have increased visceral and subcutaneous body fat due to higher androgen levels. Obesity also plays a significant role in explaining the metabolic characteristics of PCOS: patients display an atherogenic lipid profile, associated with elevated levels of low-density lipoprotein, triglycerides and cholesterol, along with reduced levels of high-density lipoprotein [3]. However, it is important to remark that these metabolic abnormalities may also be present in non-obese patients [4]. The positive correlations between hyperinsulinemia and androgen levels suggested that insulin contributes to hyperandrogenism in women with PCOS. The ovaries of PCOS patients usually maintain a normal response to insulin. A partial elucidation of this mechanism is explained by the action of insulin on the ovary through the IGF-1 receptor. This binding occurs when insulin reaches high concentrations, as in compensatory hyperinsulinemia. Insulin actions on the ovary are also mediated by the glycan molecules that contain D-chiro-inositol (DCI) [5], a different second messenger from the classical one activated by phosphorylation of the receptor at tyrosine level in other tissues. Hyperinsulinemia stimulates thecal cell proliferation, amplifies LH-mediated androgen secretion and increases expression of LH and IGF-1 receptor [6]. Furthermore, high insulin levels inhibit both the production of sex hormone binding globulin (SHBG) by the liver, causing increased levels of free testosterone [7], and the synthesis of IGF-BP1, increasing level of free IGF-1 [8].
Interestingly, excess carbohydrate intake and low-grade inflammation mutually interact with insulin resistance and hyperandrogenism to reinforce the metabolic phenotype of PCOS [9]. In fact, acute hyperglycaemia is known to increase inflammation and oxidative stress through generation of reactive oxygen species (ROS) [10]. PCOS women present a peculiar dietary pattern, characterised by reduced use of extra-virgin olive oil, legumes, seafood and nuts, a lower amount of complex carbohydrate, fiber, monounsaturated fatty acids, and higher simple carbohydrates, total fat and saturated fatty acid, compared to normal women. These nutritional habits are associated to an adverse body composition, characterised by reduced fat-free mass [11].
A univocal therapy for PCOS does not exist; the peculiar heterogeneity of this pathology requires that the treatment should be personalized, depending on the clinical presentation and needs of the patient.
The current guidelines as first-line treatment for menstrual irregularities, acne and hirsutism recommend hormonal contraceptives, at any age. Antiandrogens are suggested in the case that estroprogestinics are contraindicated or in the presence of severe hirsutism.
Metformin has long been used in therapeutic protocols, although alternatives are investigated, because of gastroenteric side effects; inositol represents an alternative approach. Anyway, metformin does not increase weight loss in patients treated with lifestyle modifications (diet and exercise programs). Therefore, diet and exercise, not metformin, should be the first line of therapy in obese women with PCOS. Metformin should be considered if the patient fails with diet and exercise [12]. Weight loss represents the most important factor to improve PCOS phenotype. A 5–10% weight loss improves ovulatory function and pregnancy rates, with reduction of insulin and free testosterone levels. However, even though lifestyle modification based on the principles of caloric restriction remains a primary therapy for PCOS and caloric restriction seems more important than macronutrient composition [13, 14], little data are available about diet's macronutrient modification as therapeutic approach [15–17]. Indeed, it is controversial whether diet composition per se has an effect on reproductive and metabolic outcomes. Blood glucose levels are affected by carbohydrate intake and regulate insulin secretion from the pancreas, so very-low carbohydrates diets may be superior to standard hypocaloric diets in terms of improving fertility, endocrine/metabolic parameters, weight loss and satiety in women with PCOS [18]. Considering the all aforementioned conditions it would be reasonable that a ketogenic diet (KD) might has positive effects on PCOS. A KD is a nutritional protocol in which carbohydrates are lower than 30 g per day or 5% of total energy intake [19–21] relative increase in the proportions of protein and fat. The reduction of the amount of circulating glucose and insulin produces a reduction of the oxidation of glucose and an increase of the fat oxidation as showed by the reduction of the respiratory ratio [22] Another important effects of KD for PCOS is the activation of AMPK and SIRT-1, even in the absence of caloric deprivation [23]. Once activated, SIRT1 and AMPK produce beneficial effects on glucose homeostasis and improve insulin sensitivity [24].
The therapeutic role of KD has been investigated for a long time and several works have supported the thesis that physiological ketosis can be useful in many pathological conditions, such as epilepsy, neurological diseases, cancer (with a ketogenic isocaloric diet) [25] and obesity, type 2 diabetes, acne, and the amelioration of respiratory and cardiovascular disease risk factors (with a generally low calorie ketogenic diet) [26–28]. This is an important aim, since the use of food as a drug has very relevant social and economic implications, both in economic and social terms. In PCOS, evidence for the effects of KD are scarce: only a small uncontrolled pilot study [29] showed a significant reduction in body weight, free testosterone, LH to FSH ratio, and fasting insulin after a KD regimen, suggesting favourable effects in affected patients. Other data describe several mechanisms consistent with the favourable effects of such diet therapy [30–32]. A recent position statement of the Italian Society of Endocrinology suggested a weight-loss program with a very low calorie ketogenic diet for overweight/obese patients with PCOS) not responsive to multicomponent standardized diet to improve insulin resistance, ovulatory dysfunctions and hyperandrogenemia, even if further controlled studies are deemed necessary to confirm the beneficial effects of KD in this clinical context [28].
Thus, aim of the present study was to determine the effects of a ketogenic diet (KD) in women of childbearing age with a diagnosis of PCOS. We hypothesized that a modified KD (KEMEPHY diet) would lead to an improvement in body weight, plasma cholesterol, triglycerides, hyperinsulinemia and hormonal outcomes.
Materials and methods
Study design
This was a 12 weeks, single-arm study. The outcome measures were body weight, BMI, FBM, LBM, FBM percentage, LBM percentage, glucose, insulin, HOMA-IR, total cholesterol, HDL, LDL, triglycerides, total testosterone, free testosterone, progesterone, estradiol, LH, FSH, DHEAS, LH/FSH ratio, SHBG and Ferriman Gallwey Score. The study protocol complied with all tenets of the Helsinki declaration. All patients provided written informed consent before the beginning of the study. The study was approved by the ethical committee of the Department of Biomedical Sciences (HEC-DSB13/16). This trial was retrospectively registered on Clinicaltrial.gov, {"type":"clinical-trial","attrs":{"text":"NCT04163120","term_id":"NCT04163120"}}NCT04163120, registered 10 November 2019, https://clinicaltrials.gov.
Participants
Twenty-four overweight women were enrolled trough public announcement in medical centers in Padova and Vicenza territory. Inclusion criteria were: diagnosis of PCOS according Rotterdam Criteria (at least 2 of 3 between oligo/amenorrhea or amenorrhea, clinical signs of hyperandrogenism and polycystic ovary confirmed with ultrasound [33]), fertile age (18–45 years); BMI ≥ 25 kg/m2, desire to lose weight; acceptance not to use contraceptives during the experimental period. Exclusion criteria were pregnancy and lactation, hormonal therapy and/or insulin-sensitizers in the last 2 months, hepatic, renal and heart diseases, local treatment for hirsutism, moreover, according to Rotterdam criteria, other aetiologies (congenital adrenal hyperplasia, androgen secreting tumours, Cushing syndrome) have been excluded. Six women were excluded for current PCOS pharmacological therapy and 2 for diagnosticated clinical hypothyroidism. One left the study after 2 weeks and one withdrew before the follow up; thus 14 subjects (age 27.5 ± 8.3 years; height 168 ± 4.3 cm; weight 81.19 ± 8.44 kg) concluded the study (Fig.1).
Flow chart of experimental design. Recruitment of patients. Further details are reported in the text
Before starting the dietary protocol participants came to the Nutrition and Exercise Physiology Laboratory of the Department of Biomedical Sciences of the University of Padua for the basal measurements. Patients underwent a detailed anamnesis and physical examination, and plasma analysis for glucose, insulin, total cholesterol, HDL, LDL, triglycerides (TGs), total testosterone, free testosterone, progesterone, estradiol, LH, FSH, DHEAS and SHBG were carried out.
Anthropometric measurements
Body weight was measured to the nearest 0.1 kg using an electronic scale (Tanita BWB-800 Medical Scales, USA), and height to the nearest 1 cm using a wall-mounted Harpenden portable stadiometer (Holtain Ltd, UK). Body mass index (BMI) was calculated in kg/m2. Waist circumference was measured as the smallest circumference between the lowest rib and the iliac crest [34, 35].
Body composition analysis
Body composition (fat body mass FBM, lean body mass LBM and visceral adipose tissue VAT) was analysed by Dual X Ray Absorptiometry (DEXA) Hologic HorizonTM QDR RSeries Bedford, Massachusetts, USA. Daily quality control scans were acquired during the study period. No hardware or software changes were made during the course of the trial. Subjects were scanned using standard positioning protocols, while wearing only light clothing. Regional analysis of the trunk and visceral adipose tissue VAT were assessed according to anatomical landmarks by the same technician using computer algorithms (Apex System).
Blood exams
Blood samples were taken from antecubital vein and collected into BD Vacutainers Tubes (SSTTM II Advance, REF 367953). After blood sampling, samples were centrifuged (4000 RPM at 4 °C using centrifuge J6-MC by Beckman). The serum, so obtained, was aliquoted and stored at − 80 °C. All samples were analysed in the same analytical session for each test using the same reagent lot and having CV intraassay < 7%. Before the analytical session, the serum samples were thawed overnight at 4 °C and then mixed. Total testosterone, DHEAS, progesterone, estradiol, FSH, LH, insulin and SHBG were measured by immunochemiluminescent method (Roche Cobas e601, Roche Diagnostics, Mannheim, Germany), blood glucose by enzymatic method with esokinase (Roche Cobas e702, Roche Diagnostics, Mannheim, Germany), total cholesterol, HDL, and LDL by enzymatic colorimetric in homogenous phase (Roche Cobas e702, Roche Diagnostics, Mannheim, Germany), TGs by an enzymatic colorimetric method (Roche Cobas e702, Roche Diagnostics, Mannheim, Germany). Free testosterone was measured by RIA radioimmunological test (Beckman Coulter). The hormonal status evaluation was performed during the follicular phase of the menstrual cycle, between the 1st and the 7th day. HOMA-IR was calculated according to the formula "insulinemia (μU/mL) × glycemia (mmol/L)/22.5. At the end of the 12 weeks, the patients were re-evaluated in the same way and the collected clinical data and DEXA scan results data was statistically analyzed. Levels of serum 3-hydroxybutyrate (BHB), BHB is the most important indicator of ketosis i.e. blood level of ketone bodies (KBs), were assessed weekly using Precision Xtra® Blood β-Ketone Test Strips and Precision Xtra® [36] (Abbott Laboratories, Illinois 60064-3500, USA) which measures blood BHB level in fresh capillary whole blood from the fingertip between 0.0 and 8.0 mmol/L. The puncture was performed with the lancet Accu-Chek Softclix (Roche, Monza MB, Italy) on clean, dry and warm fingers. Hirsutism was considered positive when the Ferriman Gallwey Score was > 8.
Diet
A modified KD protocol was used. The KEMEPHY diet [37–42] is a Mediterranean eucaloric ketogenic protocol (about 1600/1700 kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited (120 g of meat or 20 g of fish or 2 eggs) (see Table1). Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19 g/portion) and very low carbohydrate (3.5 g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts [43]. Liquid herbal extracts were used for their draining/toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis. Herbal extracts are reported in more details in our previous publication (Table2) [37].
Table 1
KEMEPHY diet composition
| g | % Total E | Kcal | |
|---|---|---|---|
| Daily total energy | 1672 ± 90 | ||
| Carbohydrate | 20.3 ± 5.2 | 4.8 ± 1.2 | 81.5 ± 18.9 |
| Fat | 132.4 ± 11.7 | 71.1 ± 9.3 | 1188.2 ± 100.2 |
| Protein | 100.8 ± 8.6 | 24.1 ± 5.6 | 403.4 ± 45.3 |
| Fats distribution | % total fats | ||
| Saturated | 38.8 ± 6.9 | ||
| Monounsaturated | 50.9 ± 6.5 | ||
| Polyunsaturated | 9.7 ± 5.6 | ||
| Protein (g/Kg body weight) | 1.23 ± 0.8 |
Table 2
Plants extract composition
| Plant extracts | Composition |
|---|---|
| Extracts 1, ml/day | Durvillea antarctica, black radish, mint, liquorice, artichoke, horsetail, burdock, dandelion, rhubarb, gentian, lemon balm, chinaroot, juniper, spear grass, elder, fucus, anise, parsley, bearberry, horehound |
| Extracts 2, ml/day | Horsetail, asparagus, birch, cypress, couch grass, corn, dandelion, grape, fennel, elder, rosehip, anise |
| Extracts 3, ml/day | Eleuthero, eurycoma longifolia, ginseng, corn, miura puama, grape, guaranà , arabic coffee, ginger |
| Extracts 4, ml/day | Linum usitatissimum L., Gelidium amansii, Rheum officinalis L., Cynara scolymus L., Matricaria chamomilla L., Gentiana lutea L., Mentha piperita L., Pimpinella anisum L., Glycyrrhiza glabra L., Raphanus sativus L., Foeniculum vulgare Mill., Althaea officinalis L., Melissa officinalis L., Juniperus communis L. |
Statistical analysis
A Student's t test was used to compare parameters before and after 12 weeks of the KD, using the software package GraphPad Prism version 8.00 for Mac, GraphPad Software, San Diego California USA. All data are expressed as mean ± standard deviation. Normality of data was assessed through the D'Agostino Pearson test. Significance was considered at a value of p < 0.05.
Results
Anthropometric and body composition measurements revealed an average weight loss of 9.43 kg (pre 81.19 ± 8.44 kg vs post 71.76 ± 6.66 kg; p < 0.0001) and significant reductions (− 3.35) of BMI (pre 28.84 ± 2.10 vs post 25.49 ± 1.69; p < 0.0001) and of FBM (− 8.29 kg) (pre 27.96 ± 5.11 kg vs post 19.67 ± 3.72 kg; p < 0.0001). LBM absolute value showed a slightly significant decrease (pre 53.23 ± 5.02 kg vs post 52.09 ± 4.60 kg), but its percentage value was slightly increased (pre 65.74 ± 3.75% vs post 72.71 ± 3.55%; p < 0.0001), with an overall improvement in body composition. VAT showed a very significant (pre 1750 ± 181.58 grams vs. post 1110,36 ± 189.23; p < 0.0001) decrease and also waist circumference decreased in a significant manner (pre 100.7 ± 4.81 vs post 96.69 ± 3.82; p = 0.0015). Anthropometric and body composition results are presented as mean ± SD in Fig.2.
Changes in anthropometric variables after 12 weeks of KD. BMI body mass index, FBM fat body mass, LBM mean body mass. Standard deviation is represented in the figure. ***p < 0.0001; **p = 0.0015; *p = 0.0205
Metabolic biomarkers
Ketone bodies were measured every other day for the first 6 days, then every 6 days. The mean BHB value was 0.31 ± 0.18 mmol/L for the first 6 days and 1.77 ± 0.55 from day 7 to day 84. Patients at the beginning of the study had a HOMA-IR higher than 2.5, confirming insulin resistance. At the end of the study, a significant decrease was observed in glucose (pre 5.10 ± 0.25 mmol/L vs post 4.64 ± 0.24 mmol/L; p < 0.0001) and insulin (pre 12.62 ± 0.48 μU/mL vs post 11.31 ± 0.60 μU/mL; p < 0.0001) and consequently in the HOMA-IR (pre 2.85 ± 0.15 vs post 2.32 ± 0.13; p < 0.0001).There were significant changes in lipid profiles with reductions in triglycerides (pre 2.31 ± 0.40 mmol/L vs post 1.87 ± 0.27 mmol/L; p < 0.0008), total cholesterol (pre 5.36 ± 0.36 mmol/L vs post 4.72 ± 0.33 mmol/L; p < 0.0001) and LDL (pre 3.11 ± 0.60 mmol/L vs post 2.33 ± 0.17 mmol/L; p < 0.0001) along with a rise in HDL levels (pre 1.79 ± 0.41 mmol/L vs post 2.02 ± 0.43 mmol/L; p < 0.0001). The data are reported as mean ± SD in Table3.
Table 3
Metabolic biomarkers before and after 12 weeks of KD
| Pre | Post | P value | |
|---|---|---|---|
| Glucose (mmol/L) | 5.10 ± 0.25 | 4.64 ± 0.24 | < 0.0001 |
| Insulin (μU/mL) | 12.62 ± 0.48 | 11.31 ± 0.60 | < 0.0001 |
| HOMA-IR | 2.85 ± 0.15 | 2.32 ± 0.13 | < 0.0001 |
| Triglycerides (mmol/L) | 2.31 ± 0.40 | 1.87 ± 0.27 | < 0.0008 |
| Total cholesterol (mmol/L) | 5.36 ± 0.36 | 4.72 ± 0.33 | < 0.0001 |
| LDL (mmol/L) | 3.11 ± 0.60 | 2.33 ± 0.17 | < 0.0001 |
| HDL (mmol/L) | 1.79 ± 0.41 | 2.02 ± 0.43 | = 0.0146 |
Endocrine biomarkers
The characteristic reversal of the LH/FSH ratio was observed at the beginning of the study and disappeared after 12 weeks (pre 2.00 ± 0.30 vs post 1.15 ± 0.20; p < 0.0001).
Compared to basal values, there was also a significant decrease in plasma concentrations of LH (pre 10.24 ± 1.43 vs post 6.41 ± 1.46; p < 0.0001), total testosterone (pre 47.43 ± 6.08 ng/dL vs post 40.71 ± 5.77 ng/dL; p < 0.0001), free testosterone (pre 0.96 ± 0.60 pg/mL vs post 0.56 ± 0.30 pg/mL; p < 0.0009), percentage of free testosterone (pre 2.05 ± 1.33% vs post 2.05 ± 1.33%; p < 0.0033) and DHEAS (pre 2.13 ± 0.26 μg/mL vs post 1.70 ± 0.20 μg/mL; p < 0.0001).
FSH values were found modestly increased, (pre 5.13 ± 0.51 vs post 5.58 ± 0.65; p = 0.0258), in accordance with the finding that usually in PCOS patients the concentration of FSH is not affected by the pathology. Estradiol levels were risen (pre 139.80 ± 14.93 pg/mL vs post 191.90 ± 38.80 pg/mL; p < 0.0001), so did progesterone (pre 12.16 ± 1.41 ng/dL vs post 21.06 ± 1.86 ng/dL; p < 0.0001). SHBG increased significantly from 26.3 ± 7.9 to 34.1 ± 8.7 nmol/L; p < 0.0001 (Fig.3).
Changes in hormonal variables after 12 weeks of KD. LH luteinizing hormone, FSH follicle stimulating hormone, DHEAs dehydroepiandrosterone sulfate, SHBG sex hormone binding globulin. Standard deviation is represented in the figure. ***p < 0.0001; **#p = 0.009; **P = 0.0082; *p = 0.0258
The Ferriman Gallwey Score was slightly reduced, although not significantly (pre 11.36 ± 1.98 vs post 10.57 ± 1.6).
Discussion
Twelve weeks of LCKD improved almost all anthropometric, biochemical and hormonal variables in a group of 14 women with diagnosed PCOS. PCOS, the most common female endocrinopathy in reproductive age, is characterized by a remarkable phenotypic heterogeneity and should not only be considered a fertility or aesthetic disorder, but a condition associated with a broad spectrum of long-term metabolic and cardio-vascular complications. The causes are not known, but the insulin resistance is considered an important factor etiopathogenetic, that involves 70% of the patients and is in most cases linked to overweight and obesity. Abdominal obesity could be linked to PCOS by a relationship in which it performs the double role of cause and effect: on the one hand, in fact, the increase in visceral fat is favored by hyperandrogenism, on the other it seems to represent an important pathogenetic factor in the development and progression of the PCOS in susceptible women [44].
The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group [45] refers that higher BMI is associated with a greater prevalence of menstrual irregularity, hyperandrogenemia and hirsutism. Adipose tissue is, in fact, an extra-glandular source of androgens and its excessive quantity can worsen the hyperandrogenism. Abdominal adipocytes are more active as endocrine cells than adipocytes of the lower portion of the body, which define gynoid obesity: they are more sensitive to catecholamines and less to insulin, with the end result of a hyperinsulinemia compensatory with low-grade inflammation, altered lipid profile, increased production of androgens and low levels of SHBG, which overall favor anovulation. Hyperinsulinemia also influences metabolic flexibility, the ability of skeletal muscle to use alternatively carbohydrates or lipids depending on the availability of energy substrates [46]. Women with PCOS have more reduced metabolic flexibility (evaluated through changes in the respiratory quotient after insulin stimulation) when have hyperandrogenism, high BMI and Insulin resistance [47, 48].
The management of PCOS is essentially symptomatic: when fertility in not the main issue, estroprogestinics represent the choice treatment and are often used for long periods of time. PCOS patients however have an increased cardiovascular risk and a prolonged use of oral contraceptives may be negative effects, so the choice of an estroprogestinic product should be done after a individual cardiovascular risk assessment in all patients. It is not the same to use an estroprogestinic product in a PCOS patient who has normal weight and has normal glucose tolerance and lipid profile or in a PCOS patient who is obese and has metabolic syndrome [49]. The patients, moreover, do not "heal" with the use of the oral contraceptives and after the suspension they often have irregularities of the cycle, so that most of them are forced to undertake therapies to induce ovulation, usually with clomiphene, as suggested the guidelines [12]. Contraception is therefore an acceptable strategy when at the same time an unwanted pregnancy is feared, but for many women a different treatment would be much more advantageous and desirable.
Guidelines [12] propose hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne in PCOS whilst metformin is suggested as treatment in women with PCOS and Type 2 diabetes or impaired glucose tolerance when lifestyle modification fail. For women with menstrual irregularities who have contraindications or intolerance to estroprogestinics, metformin is considered as second-line therapy. According to some experts [50], instead, an attempt with metformin, before administering oral contraceptives, should however be made, regardless of the contraindications, recommending contraception when there is a high risk of unwanted pregnancy. Metformin also seems to improve the subsequent ovarian response to clomiphene in infertility disorders, with comparable results in both very high and non-BMI patients. However, metformin is not free from side effects, which often compromise compliance.
The debate on therapy is therefore still on and there is often confusion, both among the health professionals and among the patients, on who is responsible for the choice of treatment: women usually turn to the gynecologist in the first instance, because have problems of menstrual irregularity and fertility, with disappointment of the endocrinologist. Moreover, many women unwillingly accept the idea of continuous medicalization and seek different solutions.
In this context a central role of a nutritionist could be envisaged, in the light of the indications of the same guidelines, which now believe that a decisive element in the management of PCOS is the modification of lifestyle and nutrition.
Several dietary models have been proposed to correct the metabolic alterations of PCOS, but no one has reached, at the moment, a scientific validation as the best to recommend and it is still not clear even if normal weight, or overweight women may take benefit from a suitable dietary program to improve insulin resistance without caloric restriction. In this context KDs could be considered, as a nutraceutical therapy aimed to increase insulin sensitivity. The data available in the literature [26, 30–32], although few, confirm the assumption that a KD, correcting hyperinsulinemia and improving body composition, can contribute to the normalization of the clinical picture in PCOS. During fasting or a carbohydrate restriction such as a KD, blood insulin concentration decreases, while glucagon increases to maintain the normal blood glucose level, first through glycogen stores, then through the β-oxidation of fatty acids stored in fat depots. Approximately 3–5 days after a very low carbohydrate diet, when the concentration of KBs begins to grow, hunger considerably decreases, but maintaining a state of well-being [51]. The advantage is further substantial if we compare common hypocaloric diets which are strongly restrictive towards the lipids, which keep the level of the orexigenic hormones up to 12 months from the suspension of the diet [52, 53]. In a physiological state of ketosis as during fasting, thanks to the considerable consumption of ketones by the CNS and the balance between insulin and glucagon, ketonemia reaches maximum levels of 7–8 mmol/L [26], with no change in the pH of the blood. During a LCKD the levels of KBs are usually between 0.5–0.6 and 4 [54–56] and a nutritional ketosis could be defined as a blood ketones > 0.5 mmol/L [57–61] Indeed, our subjects showed an steep increase in blood BHB during the first 6 days reaching, at the end of the first week 0.55 ± 0.27 mmol/L BHB, whilst the mean value from day 7 to day 84 was 1.77 ± 0.55 BHB. It is therefore essential to make a clear distinction between physiological ketosis (KD, fasting) and a pathological ketosis, such as that which can occur in diabetes when hyperglycemia and insulin deficiency cause uncontrolled rates of KBs and the ketonemia may exceed 20 mmol/L, exposing to the risk of severe acidosis. Fasting ketosis, however, leads to a loss of protein reserves, especially affecting muscle mass and generating a global state of decay. Conversely, the ketogenic diet, while maintaining a state of ketosis over time due to the limitation of carbohydrates, ensures an adequate supply of protein, preserving the tissues [20]. It is important to underline that a classic KD is not a high-protein diet, but usually has high-fat, adequate-protein, low-carbohydrate content. In fact, an excess of proteins increases gluconeogenesis in the long run, thus affecting the synthesis of KBs: in the first days of a KD the neoglucogenesis from amino acids represents the main source of glucose to keep the glycemia stable, then the demand for amino acids decreases and glucose is synthesized from the glycerol released from adipose tissue by triglyceride hydrolysis. Our diet was a low calorie ketogenic diet in which the amount of protein was high if we consider percentage (32%) but normal if we consider grams of protein per kilogram of body weight (1.23 g pro/Kg bw). Such low calorie approach is more feasible during a KD (LCKD) because it is well known that ketones reduce appetite probably through direct brain actions of KBs [51, 62].
The theoretical assumptions for the use of KD in PCOS are based on the observation that the physiological ketosis induced by a low intake of carbohydrates reduces the levels of circulating insulin and consequently also those of IGF-1, thus suppressing the stimulus on the production of androgens, both ovarian and adrenal. The reduction of circulating lipids, low-grade inflammation and oxidative stress also helps prevent cardiovascular complications [19, 26, 27, 41, 63–65]. Indeed PCOS patients are characterized by higher circulating lymphocytes, monocytes, eosinophilic granulocytes, as well as higher CRP, TNF-α and IL-6, revealing peripheral inflammation. In addition, polycystic ovaries show persistent chronic inflammation with a larger number of infiltrating inflammatory cells. As TNF-a and IL-6 are known to induce insulin resistance, stimulate androgen production and disrupt the hypothalamic-pituitary-ovarian axis, the increased number of lymphocytes could be an factor triggering chronic inflammation and altered hormone secretion [66]. Importantly, hyperglycemia can worsen inflammation and in PCOS patients glucose ingestion induces an inflammatory response that is independent of obesity [67]. Ketogenic diet has demonstrated to be able to improve inflammatory markers per se [41, 68] also due to the action of one of the ketone bodies: 3-hydroxybutyrate [69]. The 14 patients enrolled in this study lost weight with a significant reduction in FBM accompanied by minimal loss of LBM. This result can be related to the inhibition of mTOR by AMPK [70, 71], which is a protective role for muscle anabolism: using KD, in fact, we never expect to get hypertrophy, but to keep the lean mass almost unchanged [72], to difference in extreme caloric restriction diets where the loss is usually more pronounced.
Insulin resistance was significantly reduced, falling below the HOMA-IR threshold of 2.5; also cholesterol and triglycerides were significantly lowered. Androgens decreased significantly, as did LH and LH/FSH, suggesting a regression of the PCOS hormonal anomalies. The improvement in the Ferriman Gallwey Score did not reach statistical significance, however, we can be assumed that 12 weeks were not sufficient to observe a decrease in hirsutism scores: the hair cycle, in fact, depending on the body area can last for some months and it is known that pharmacological therapy based on antiandrogens takes from 6 to 12 months to obtain a good reduction of the score.
Conclusions
The results of our study are suggestive for a use of the KD as a possible therapeutic aid in PCOS, to be followed by a more balanced dietary regimen, but always with particular attention to the amount of carbohydrates. The duration of KD is still a question: there is no evidence of side effects in the short term, they are considered safe for short cycles. Less information is available on diets in the long term, but the experience gained in the field of epilepsy and GLUT-1 deficiency syndrome [73–79] supports a possible use also for prolonged periods. It is plausible to hypothesize the setting of protocols to be repeated in cycles over time, interspersed with periods of balanced regime.
Some limitations of the study need to be considered. The first is that the effects of a KD on other outcomes as oligomenorrea and infertility were not assessed. Second, an OGTT for glucose and insulin would have added more information about the metabolic effects of a KD, unfortunately the experimental setting didn't allowed us to perform this analysis; finally, the small sample size and the single arm design therefore further confirmations are required, possibly increasing the number of subjects, extending the treatment period, and match a low calorie ketogenic diet with a low calorie Mediterranean diet.
Acknowledgements
Not applicable.
Abbreviations
| PCOS | Polycystic ovary syndrome |
| KD | Ketogenic diet |
| LCKD | Low calorie ketogenic diet |
| IGF-1 | Insulin-like growth factor-1 |
| AMPK | Adenosine 5′-monophosphate-activated protein kinase |
| HOMA-IR | Homeostasis model assessment–insulin-resistance |
| mTOR | Mammalian target of rapamycin |
| IGFBP-1 | Insulin-like growth factor binding protein 1 |
Authors' contributions
AP conceived the study, supervised the experiment and wrote the manuscript, LM wrote the manuscript and analyzed the data, MCG collected and analysed the data, AB analysed and interpreted the patient data regarding, MC was a major contributor in writing the manuscript. All authors read and approved the final manuscript.
Funding
Department institutional research funding was used.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All patients provided written informed consent before the beginning of the study. The study was approved by the ethical committee of the Department of Biomedical Sciences (HEC-DSB13/16).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am. 2015;99(1):221–235. doi: 10.1016/j.mcna.2014.09.003. [PubMed] [CrossRef] [Google Scholar]
2. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13. doi: 10.2147/CLEP.S37559. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Palomba S, Falbo A, Chiossi G, Muscogiuri G, Fornaciari E, Orio F, et al. Lipid profile in nonobese pregnant women with polycystic ovary syndrome: a prospective controlled clinical study. Steroids. 2014;88:36–43. doi: 10.1016/j.steroids.2014.06.005. [PubMed] [CrossRef] [Google Scholar]
4. El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124. doi: 10.3389/fphys.2016.00124. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
5. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16(11–12):543–552. doi: 10.2119/molmed.2010.00107. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
6. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14(1):38. doi: 10.1186/s12958-016-0173-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin resistance. Clin Endocrinol. 2013;78(3):321–329. doi: 10.1111/cen.12086. [PubMed] [CrossRef] [Google Scholar]
8. Homburg R, Pariente C, Lunenfeld B, Jacobs HS. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod. 1992;7(10):1379–1383. doi: 10.1093/oxfordjournals.humrep.a137577. [PubMed] [CrossRef] [Google Scholar]
9. Barrea L, Marzullo P, Muscogiuri G, Di Somma C, Scacchi M, Orio F, et al. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome. Nutr Res Rev. 2018;31(2):291–301. doi: 10.1017/S0954422418000136. [PubMed] [CrossRef] [Google Scholar]
10. Ceriello A. Acute hyperglycaemia and oxidative stress generation. Diab Med. 1997;14(Suppl 3):S45–S49. doi: 10.1002/(SICI)1096-9136(199708)14:3+<S45::AID-DIA444>3.3.CO;2-I. [PubMed] [CrossRef] [Google Scholar]
11. Barrea L, Arnone A, Annunziata G, Muscogiuri G, Laudisio D, Salzano C, et al. Adherence to the mediterranean diet, dietary patterns and body composition in women with polycystic ovary syndrome (PCOS) Nutrients. 2019;11(10):2278. doi: 10.3390/nu11102278. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592. doi: 10.1210/jc.2013-2350. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697. doi: 10.1016/S0140-6736(07)61345-2. [PubMed] [CrossRef] [Google Scholar]
14. Hoeger KM, Oberfield SE. Do women with PCOS have a unique predisposition to obesity? Fertil Steril. 2012;97(1):13–17. doi: 10.1016/j.fertnstert.2011.11.026. [PubMed] [CrossRef] [Google Scholar]
15. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril. 2004;81(3):630–637. doi: 10.1016/j.fertnstert.2003.08.023. [PubMed] [CrossRef] [Google Scholar]
16. Moran LJ, Noakes M, Clifton PM, Wittert GA, Williams G, Norman RJ. Short-term meal replacements followed by dietary macronutrient restriction enhance weight loss in polycystic ovary syndrome. Am J Clin Nutr. 2006;84(1):77–87. doi: 10.1093/ajcn/84.1.77. [PubMed] [CrossRef] [Google Scholar]
17. Tsagareli V, Noakes M, Norman RJ. Effect of a very-low-calorie diet on in vitro fertilization outcomes. Fertil Steril. 2006;86(1):227–229. doi: 10.1016/j.fertnstert.2005.12.041. [PubMed] [CrossRef] [Google Scholar]
18. Frary JM, Bjerre KP, Glintborg D, Ravn P. The effect of dietary carbohydrates in women with polycystic ovary syndrome: a systematic review. Minerva Endocrinol. 2016;41(1):57–69. [PubMed] [Google Scholar]
19. Paoli A. Ketogenic diet for obesity: friend or foe? Int J Environ Res Public Health. 2014;11(2):2092–2107. doi: 10.3390/ijerph110202092. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Paoli A, Bianco A, Grimaldi KA. The ketogenic diet and sport: a possible marriage? Exerc Sport Sci Rev. 2015;43(3):153–162. doi: 10.1249/JES.0000000000000050. [PubMed] [CrossRef] [Google Scholar]
21. Muscogiuri G, Barrea L, Laudisio D, Pugliese G, Salzano C, Savastano S, et al. The management of very low-calorie ketogenic diet in obesity outpatient clinic: a practical guide. J Transl Med. 2019;17(1):356. doi: 10.1186/s12967-019-2104-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Rubini A, Bosco G, Lodi A, Cenci L, Parmagnani A, Grimaldi K, et al. Erratum to: effects of twenty days of the ketogenic diet on metabolic and respiratory parameters in healthy subjects. Lung. 2017;195(1):155. doi: 10.1007/s00408-016-9958-0. [PubMed] [CrossRef] [Google Scholar]
23. Draznin B, Wang C, Adochio R, Leitner JW, Cornier MA. Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. Horm Metab Res. 2012;44(9):650–655. doi: 10.1055/s-0032-1312656. [PubMed] [CrossRef] [Google Scholar]
24. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab. 2010;298(4):E751–E760. doi: 10.1152/ajpendo.00745.2009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Erickson N, Boscheri A, Linke B, Huebner J. Systematic review: isocaloric ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34(5):72. doi: 10.1007/s12032-017-0930-5. [PubMed] [CrossRef] [Google Scholar]
26. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67(8):789–796. doi: 10.1038/ejcn.2013.116. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013;110(7):1178–1187. doi: 10.1017/S0007114513000548. [PubMed] [CrossRef] [Google Scholar]
28. Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, et al. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of endocrinology (SIE) J Endocrinol Invest. 2019;42(11):1365–1386. doi: 10.1007/s40618-019-01061-2. [PubMed] [CrossRef] [Google Scholar]
29. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr Metab. 2005;2:35. doi: 10.1186/1743-7075-2-35. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Douglas CC, Gower BA, Darnell BE, Ovalle F, Oster RA, Azziz R. Role of diet in the treatment of polycystic ovary syndrome. Fertil Steril. 2006;85(3):679–688. doi: 10.1016/j.fertnstert.2005.08.045. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Kulak D, Polotsky AJ. Should the ketogenic diet be considered for enhancing fertility? Maturitas. 2013;74(1):10–13. doi: 10.1016/j.maturitas.2012.10.003. [PubMed] [CrossRef] [Google Scholar]
32. McGrice M, Porter J. The effect of low carbohydrate diets on fertility hormones and outcomes in overweight and obese women: a systematic review. Nutrients. 2017;9(3):204. doi: 10.3390/nu9030204. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
33. Rotterdam EA-SPCWG Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi: 10.1016/j.fertnstert.2003.10.004. [PubMed] [CrossRef] [Google Scholar]
34. Wang J, Thornton JC, Bari S, Williamson B, Gallagher D, Heymsfield SB, et al. Comparisons of waist circumferences measured at 4 sites. Am J Clin Nutr. 2003;77(2):379–384. doi: 10.1093/ajcn/77.2.379. [PubMed] [CrossRef] [Google Scholar]
35. Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, et al. Waist circumference and cardiometabolic risk: a consensus statement from SHAPING America's health: association for weight management and obesity prevention; NAASO, The obesity society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr. 2007;85(5):1197–1202. doi: 10.1093/ajcn/85.5.1197. [PubMed] [CrossRef] [Google Scholar]
36. Voulgari C, Tentolouris N. The performance of a glucose-ketone meter in the diagnosis of diabetic ketoacidosis in patients with type 2 diabetes in the emergency room. Diab Technol Ther. 2010;12(7):529–535. doi: 10.1089/dia.2010.0011. [PubMed] [CrossRef] [Google Scholar]
37. Paoli A, Cenci L, Grimaldi KA. Effect of ketogenic mediterranean diet with phytoextracts and low carbohydrates/high-protein meals on weight, cardiovascular risk factors, body composition and diet compliance in italian council employees. Nutr J. 2011;10(1):112. doi: 10.1186/1475-2891-10-112. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Paoli A, Bianco A, Grimaldi KA, Lodi A, Bosco G. Long term successful weight loss with a combination biphasic ketogenic mediterranean diet and mediterranean diet maintenance protocol. Nutrients. 2013;5(12):5205–5217. doi: 10.3390/nu5125205. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
39. Paoli A, Cenci L, Fancelli M, Parmagnani A, Fratter A, Cucchi A, et al. Ketogenic diet and phytoextracts comparison of the efficacy of Mediterranean, zone and tisanoreica diet on some health risk factors. Agro Food Ind Hi-Tech. 2010;21(4):24–29. [Google Scholar]
40. Paoli A, Grimaldi K, D'Agostino D, Cenci L, Moro T, Bianco A, et al. Ketogenic diet does not affect strength performance in elite artistic gymnasts. J Int Soc Sports Nutr. 2012;9(1):34. doi: 10.1186/1550-2783-9-34. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Paoli A, Moro T, Bosco G, Bianco A, Grimaldi KA, Camporesi E, et al. Effects of n-3 polyunsaturated fatty acids (omega-3) supplementation on some cardiovascular risk factors with a ketogenic Mediterranean diet. Mar Drugs. 2015;13(2):996–1009. doi: 10.3390/md13020996. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. Bosco G, Rizzato A, Quartesan S, Camporesi E, Mangar D, Paganini M, et al. Effects of the Ketogenic diet in overweight divers breathing enriched air nitrox. Sci Rep. 2018;8(1):2655. doi: 10.1038/s41598-018-20933-w. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Lodi A, Karsten B, Bosco G, Gomez-Lopez M, Brandao PP, Bianco A, et al. The effects of different high-protein low-carbohydrates proprietary foods on blood sugar in healthy subjects. J Med Food. 2016;19(11):1085–1095. doi: 10.1089/jmf.2016.0072. [PubMed] [CrossRef] [Google Scholar]
44. Armani A, Berry A, Cirulli F, Caprio M. Molecular mechanisms underlying metabolic syndrome: the expanding role of the adipocyte. FASEB J. 2017;31(10):4240–4255. doi: 10.1096/fj.201601125RRR. [PubMed] [CrossRef] [Google Scholar]
45. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38 e25. doi: 10.1016/j.fertnstert.2011.09.024. [PubMed] [CrossRef] [Google Scholar]
46. Kelley DE. Skeletal muscle fat oxidation: timing and flexibility are everything. J Clin Invest. 2005;115(7):1699–1702. doi: 10.1172/JCI25758. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Kim JY, Tfayli H, Michaliszyn SF, Arslanian S. Impaired lipolysis, diminished fat oxidation, and metabolic inflexibility in obese girls with polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103(2):546–554. doi: 10.1210/jc.2017-01958. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
48. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98(6):2581–2588. doi: 10.1210/jc.2013-1161. [PubMed] [CrossRef] [Google Scholar]
49. Carmina E. Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36(5):358–363. [PubMed] [Google Scholar]
50. Orio F, Palomba S. Reproductive endocrinology: new guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol. 2014;10(3):130–132. doi: 10.1038/nrendo.2013.248. [PubMed] [CrossRef] [Google Scholar]
51. Paoli A, Bosco G, Camporesi EM, Mangar D. Ketosis, ketogenic diet and food intake control: a complex relationship. Front Psychol. 2015;6:27. doi: 10.3389/fpsyg.2015.00027. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. Eur J Clin Nutr. 2013;67:759–764. doi: 10.1038/ejcn.2013.90. [PubMed] [CrossRef] [Google Scholar]
53. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. New Engl J Med. 2011;365(17):1597–1604. doi: 10.1056/NEJMoa1105816. [PubMed] [CrossRef] [Google Scholar]
54. Fery F, Balasse EO. Ketone body production and disposal in diabetic ketosis. A comparison with fasting ketosis. Diabetes. 1985;34(4):326–332. doi: 10.2337/diab.34.4.326. [PubMed] [CrossRef] [Google Scholar]
55. Cahill GF., Jr Fuel metabolism in starvation. Annu Rev Nutr. 2006;26:1–22. doi: 10.1146/annurev.nutr.26.061505.111258. [PubMed] [CrossRef] [Google Scholar]
56. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF., Jr Ketone bodies, potential therapeutic uses. IUBMB Life. 2001;51(4):241–247. doi: 10.1080/152165401753311780. [PubMed] [CrossRef] [Google Scholar]
57. Taboulet P, Deconinck N, Thurel A, Haas L, Manamani J, Porcher R, et al. Correlation between urine ketones (acetoacetate) and capillary blood ketones (3-beta-hydroxybutyrate) in hyperglycaemic patients. Diab Metab. 2007;33(2):135–139. doi: 10.1016/j.diabet.2006.11.006. [PubMed] [CrossRef] [Google Scholar]
58. Harvey C, Schofield GM, Williden M. The use of nutritional supplements to induce ketosis and reduce symptoms associated with keto-induction: a narrative review. PeerJ. 2018;6:e4488. doi: 10.7717/peerj.4488. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
59. Laffel L. Sick-day management in type 1 diabetes. Endocrinol Metab Clin North Am. 2000;29(4):707–723. doi: 10.1016/S0889-8529(05)70160-2. [PubMed] [CrossRef] [Google Scholar]
60. Mesa J, Salcedo D, Calle Hde L, Delgado E, Novoa J, Hawkins F, et al. Detection of ketonemia and its relationship with hyperglycemia in type 1 diabetic patients. Diab Res Clin Pract. 2006;72(3):292–297. doi: 10.1016/j.diabres.2005.10.008. [PubMed] [CrossRef] [Google Scholar]
61. Krebs HA. The regulation of the release of ketone bodies by the liver. Adv Enzyme Regul. 1966;4:339–354. doi: 10.1016/0065-2571(66)90027-6. [PubMed] [CrossRef] [Google Scholar]
62. Paoli A. Booster ketones: battling hunger. Obesity. 2018;26(2):252–253. doi: 10.1002/oby.22099. [PubMed] [CrossRef] [Google Scholar]
63. Perez-Guisado J. Ketogenic diets: additional benefits to the weight loss and unfounded secondary effects. Arch Latinoam Nutr. 2008;58(4):323–329. [PubMed] [Google Scholar]
64. Sharman MJ, Kraemer WJ, Love DM, Avery NG, Gomez AL, Scheett TP, et al. A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J Nutr. 2002;132(7):1879–1885. doi: 10.1093/jn/132.7.1879. [PubMed] [CrossRef] [Google Scholar]
65. Volek JS, Gomez AL, Kraemer WJ. Fasting lipoprotein and postprandial triacylglycerol responses to a low-carbohydrate diet supplemented with n-3 fatty acids. J Am Coll Nutr. 2000;19(3):383–391. doi: 10.1080/07315724.2000.10718935. [PubMed] [CrossRef] [Google Scholar]
66. Xiong YL, Liang XY, Yang X, Li Y, Wei LN. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;159(1):148–150. doi: 10.1016/j.ejogrb.2011.07.012. [PubMed] [CrossRef] [Google Scholar]
67. Gonzalez F. Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids. 2012;77(4):300–305. doi: 10.1016/j.steroids.2011.12.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
68. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21(3):263–269. doi: 10.1038/nm.3804. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
69. Puchalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 2017;25(2):262–284. doi: 10.1016/j.cmet.2016.12.022. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
70. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–322. doi: 10.1016/j.molcel.2010.09.026. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
71. Canto C, Auwerx J. Calorie restriction: is AMPK a key sensor and effector? Physiology. 2011;26(4):214–224. doi: 10.1152/physiol.00010.2011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
72. Paoli A, Cancellara P, Pompei P, Moro T. Ketogenic diet and skeletal muscle hypertrophy: a frenemy relationship? J Hum kinet. 2019;68:233–247. doi: 10.2478/hukin-2019-0071. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
73. Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics. 2005;36(5):302–308. doi: 10.1055/s-2005-872843. [PubMed] [CrossRef] [Google Scholar]
74. Bergqvist AG. Long-term monitoring of the ketogenic diet: do's and don'ts. Epilepsy Res. 2012;100(3):261–266. doi: 10.1016/j.eplepsyres.2011.05.020. [PubMed] [CrossRef] [Google Scholar]
75. Bertoli S, Trentani C, Ferraris C, De Giorgis V, Veggiotti P, Tagliabue A. Long-term effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: a case series. Nutrition. 2014;30(6):726–728. doi: 10.1016/j.nut.2014.01.005. [PubMed] [CrossRef] [Google Scholar]
76. De Amicis R, Leone A, Lessa C, Foppiani A, Ravella S, Ravasenghi S, et al. Long-term effects of a classic ketogenic diet on ghrelin and leptin concentration: a 12-month prospective study in a cohort of Italian children and adults with GLUT1-deficiency syndrome and drug resistant epilepsy. Nutrients. 2019;11(8):1716. doi: 10.3390/nu11081716. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
77. Dressler A, Stocklin B, Reithofer E, Benninger F, Freilinger M, Hauser E, et al. Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy–the Austrian experience. Seizure. 2010;19(7):404–408. doi: 10.1016/j.seizure.2010.06.006. [PubMed] [CrossRef] [Google Scholar]
78. Heussinger N, Della Marina A, Beyerlein A, Leiendecker B, Hermann-Alves S, Dalla Pozza R, et al. 10 patients, 10 years—long term follow-up of cardiovascular risk factors in Glut1 deficiency treated with ketogenic diet therapies: a prospective, multicenter case series. Clin Nutr. 2018;37:2246–2251. doi: 10.1016/j.clnu.2017.11.001. [PubMed] [CrossRef] [Google Scholar]
79. Patel A, Pyzik PL, Turner Z, Rubenstein JE, Kossoff EH. Long-term outcomes of children treated with the ketogenic diet in the past. Epilepsia. 2010;51(7):1277–1282. doi: 10.1111/j.1528-1167.2009.02488.x. [PubMed] [CrossRef] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045520/